<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05629377</url>
  </required_header>
  <id_info>
    <org_study_id>22-006348</org_study_id>
    <secondary_id>R01HD106096</secondary_id>
    <nct_id>NCT05629377</nct_id>
  </id_info>
  <brief_title>Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health (ARCH)</brief_title>
  <acronym>ARCH</acronym>
  <official_title>Hypothalamic Amenorrhea as a Fertility Status Marker for Cardiovascular Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hypothalamic amenorrhea (HA) occurs during reproductive years and results in stopped&#xD;
      menstrual cycles and infertility which can be prolonged from months to years and is&#xD;
      characterized by varying combinations of psychosocial stress, anxiety, high levels of&#xD;
      physical activity, and/or weight loss. Data from our group indicates that one-third of women&#xD;
      with HA (mean age: 27 yrs) have preclinical cardiovascular disease (CVD) measured&#xD;
      noninvasively as vascular dysfunction and vascular inflammation. This study will use HA as a&#xD;
      marker of fertility status for cardiovascular health and perform dense-phenotyping using&#xD;
      remote patient monitoring (FitBit) and patient reported outcomes (questionnaires) to&#xD;
      determine which HA phenotypes are related to preclinical CVD and inflammation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2023</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Hypothalamic Amenorrhea (HA) duration</measure>
    <time_frame>3 months</time_frame>
    <description>Duration of HA by month of amenorrhea (absence of menstruation)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular dysfunction</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by reactive hyperemic index (RHI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Psychosocial stress</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by NIH PROMISÂ® short-form questionnaires</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Perceived stress</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by the validate perceived stress scale questionnaire, a 10-item questionnaire, scores range from 0 to 40; higher scores indicate higher levels of perceived stress.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Step count</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by Fitbit Versa 2 watch that tracks steps per day, active and resting heart rate, sleep hours per day</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physical activity level</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by Fitbit Versa 2 watch that tracks amount of light physical activity, moderate, and vigorous activity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate</measure>
    <time_frame>3 months</time_frame>
    <description>Measured by Fitbit Versa 2 watch that tracks heart rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Caloric intake and nutrition</measure>
    <time_frame>3 days</time_frame>
    <description>Measured using a self-reported food diary</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vascular inflammation</measure>
    <time_frame>3 months</time_frame>
    <description>concentration of cytokines multiplex immunoassay platform</description>
  </primary_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Hypothalamic Amenorrhea</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Premenopausal women with hypothalamic amenorrhea at Mayo Clinic Florida.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Secondary amenorrhea of 3 or more consecutive months duration&#xD;
&#xD;
          -  Include the screening hormones (eg, estradiol (E2) &lt; 50 pg/ml, Follicle-Stimulating&#xD;
             Hormone (FSH) &lt;10 mIU/ml, and Luteinizing Hormone (LH) &lt; 10mIU/ml and other&#xD;
             HA-defining hormones); or clinical diagnosis of HA by medical providers.&#xD;
&#xD;
          -  Pre-menopause status.&#xD;
&#xD;
          -  Able to give informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A diagnosis for secondary amenorrhea including prolactinoma, Polycystic Ovary Syndrome&#xD;
             (PCOS), premature ovarian insufficiency, pituitary surgery, infection or infarction&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Psychotropic/illicit drug use&#xD;
&#xD;
          -  Mental/neurological/major psychological disorders (other than depression and anxiety).&#xD;
&#xD;
          -  Parturition/lactating in the last 6-12 months.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chrisandra Shufelt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chrisandra Shufelt, MD</last_name>
    <phone>904-953-2160</phone>
    <email>Shufelt.Chrisandra@mayo.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrisandra Shufelt, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>February 2023</verification_date>
  <study_first_submitted>October 14, 2022</study_first_submitted>
  <study_first_submitted_qc>November 17, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 29, 2022</study_first_posted>
  <last_update_submitted>February 7, 2023</last_update_submitted>
  <last_update_submitted_qc>February 7, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Chrisandra L. Shufelt, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Functional Hypothalamic Amenorrhea</keyword>
  <keyword>Amenorrhea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amenorrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

